To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

2019 San Antonio Breast Cancer Symposium

Highlights and updates from the 2019 San Antonio Breast Cancer Symposium (SABCS), where oncology professionals, patients, and advocates from around the globe gather to discuss and present the latest updates in the field of breast cancer oncology.
Tom Castles
Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.
Khevin Barnes
At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.
Tom Castles
Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.
Tom Castles
Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.
Tom Castles
Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.
Tom Castles and Katie Kosko
Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.
Khevin Barnes
This massive event for women with breast cancer just may be “man’s breast friend”.
Tom Castles and Katie Kosko
Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.
Tom Castles
Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.
Tom Castles and Katie Kosko
Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

Sign In

Not a member? Sign up now!
Continue without login